Active Biotech to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
The presentation will include the Phase III projects laquinimod, a novel oral immunomodulatory drug for the treatment of multiple sclerosis, which is licensed to Teva Pharmaceutical Industries Ltd and ANYARA, Active Biotech's novel concept for tumor therapy in a Phase III study for renal cell cancer. Also, data from the prostate cancer project TASQ will be presented and an update on the SLE project 57-57 as well as the new project around the mode of action of the quinoline technology.
The audio and slide presentation will be webcasted live and can be accessed via the Active Biotech web site.
The presentation will take place on November 11, at 2:00 pm US Eastern Time / 20:00 Central European Time.
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI), headquartered in Sweden, is a biotechnology company with R&D focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® for RA. Please visit www.activebiotech.com
for more information.
Active Biotech AB
Göran Forsberg, VP Communication & Business Development
P.O. Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00
Active Biotech is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 08:30 a.m. CET on November 6, 2008.